Case Report: Detection of a Novel Germline
PALB2
breast-cancer risk
deletion
hereditary breast cancer
surveillance
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
09
2020
accepted:
05
02
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
The partner and localizer of
Identifiants
pubmed: 33718150
doi: 10.3389/fonc.2021.602523
pmc: PMC7943848
doi:
Types de publication
Case Reports
Langues
eng
Pagination
602523Informations de copyright
Copyright © 2021 De Angelis, Nardelli, Concolino, Pagliuca, Setaro, De Paolis, De Placido, Forestieri, Scaglione, Ranieri, Lombardo, Pastore, De Placido and Capoluongo.
Déclaration de conflit d'intérêts
CDA was a consultant/advisory board member for Novartis, Eli Lilly, and Pfizer. SDP had declared honoraria from Roche, Pfizer, Astra-Zeneca, Novartis, Celgene, Eli Lilly, Amgen and Eisai. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Trends Biochem Sci. 2019 Mar;44(3):226-240
pubmed: 30638972
Nature. 2007 Mar 15;446(7133):316-9
pubmed: 17287723
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7
pubmed: 22006311
J Clin Oncol. 2020 Dec 20;38(36):4274-4282
pubmed: 33119476
Breast Cancer Res. 2010;12(6):R109
pubmed: 21182766
Oncotarget. 2016 Nov 8;7(45):74227-74235
pubmed: 27732944
J Thromb Haemost. 2013 Jan;11(1):195-7
pubmed: 23140572
J Clin Oncol. 2020 Mar 1;38(7):674-685
pubmed: 31841383
J Med Genet. 2016 Dec;53(12):800-811
pubmed: 27595995
Mol Cell. 2006 Jun 23;22(6):719-729
pubmed: 16793542
Lancet Oncol. 2015 Jun;16(6):638-44
pubmed: 25959805
Science. 2009 Apr 10;324(5924):217
pubmed: 19264984
Int J Cancer. 2019 Jul 15;145(2):390-400
pubmed: 30613976
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Nat Rev Cancer. 2016 Sep;16(9):599-612
pubmed: 27515922
Nat Commun. 2018 Oct 4;9(1):4083
pubmed: 30287823
JAMA Oncol. 2017 Sep 1;3(9):1190-1196
pubmed: 28418444
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391
pubmed: 32259785
Cochrane Database Syst Rev. 2018 Apr 05;4:CD002748
pubmed: 29620792
J Hum Genet. 2020 Jan;65(2):199-205
pubmed: 31619740
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
J Med Genet. 2017 Nov;54(11):732-741
pubmed: 28779002
JAMA Oncol. 2017 Sep 1;3(9):1245-1248
pubmed: 28033443
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Clin Genet. 2010 Nov;78(5):490-4
pubmed: 20412113
Oncogene. 2017 Jul 20;36(29):4161-4170
pubmed: 28319063
Front Oncol. 2020 Feb 28;10:301
pubmed: 32185139
Nat Genet. 2007 Feb;39(2):165-7
pubmed: 17200668
JAMA Oncol. 2016 Apr;2(4):482-90
pubmed: 26720728
N Engl J Med. 2008 Nov 13;359(20):2143-53
pubmed: 19005198
Nat Struct Mol Biol. 2010 Oct;17(10):1247-54
pubmed: 20871615
Ann Oncol. 2016 Nov;27(11):2046-2052
pubmed: 27502725
Cancer. 2014 Apr 1;120(7):963-7
pubmed: 24415441
NPJ Breast Cancer. 2019 Nov 1;5:38
pubmed: 31700994
J Natl Cancer Inst. 2020 Dec 14;112(12):1242-1250
pubmed: 32107557
J Clin Oncol. 2020 Jun 20;38(18):2080-2106
pubmed: 32243226
J Natl Cancer Inst. 2015 Aug 27;107(11):
pubmed: 26315354
Nat Commun. 2014;5:3156
pubmed: 24448499